Aytu BioPharma, Inc (AYTU) stock
Close on Nov 11, 2026Market cap $19.67MP/E –Yield –
Aytu BioPharma, Inc saw revenue fall 13.3% to $57.57M over the twelve months to Jun 30, 2026. Free cash flow was $3.25M. At the latest close the market valued the company at $19.67M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $19.67M
- P/E ratio
- –
- Price to sales
- 0.34
- Price to book
- 0.56
- Dividend yield
- –
- Free cash flow yield
- 16.53%
Fundamentals
- Revenue
- $57.57M
- Net income
- -$14.25M
- EPS, diluted
- -$1.66
- Free cash flow
- $3.25M
- Book value per share
- $1.83
- Diluted shares
- 19M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $1.81
- Open
- $1.84
- Day's range
- $1.81 – $1.90
- Volume
- 11,438
- Average volume (20 days)
- 26,929
- Beta (5 years)
- 1.06
- 52-week range
- $1.75 – $3.06
- RSI (14 days)
- 35.7
- Volatility (1 year)
- 44.1%
- Relative volume
- 0.35×
- WACC
- 10.7%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AYTU | S&P 500 | Difference | AYTU per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.6% | -2.4% | −8.2 pts | ||
| 3 months | -24.6% | -1.2% | −23.4 pts | ||
| Year to date | -30.4% | +12.3% | −42.7 pts | ||
| 1 year | -13.8% | +12.4% | −26.3 pts | ||
| 3 years | -37.8% | +78.8% | −116.6 pts | -14.6% | +21.4% |
| 5 years | -96.3% | +75.2% | −171.4 pts | -48.2% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -66.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aytu BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Results
About Aytu BioPharma
Pharmaceutical Preparations
Aytu BioPharma, Inc. is a pharmaceutical company that commercializes prescription therapeutics primarily focused on central nervous system disorders. The company operates in a single business segment consisting of prescription medications sold to pharmaceutical wholesalers, distributors, and pharmacies. Its lead commercial product is EXXUA, an extended-release tablet indicated for the treatment of major depressive disorder in adults. The company also markets an attention deficit hyperactivity disorder portfolio comprising Adzenys XR-ODT and Cotempla XR-ODT, along with an authorized generic, as well as a pediatric portfolio featuring Karbinal ER, an extended-release oral suspension for treating allergic conditions.
Company profile, executives and historyAytu BioPharma stock: common questions
What is Aytu BioPharma's stock price?
AYTU closed at $1.81 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.75 and $3.06.
What is Aytu BioPharma's market cap?
Aytu BioPharma was worth $19.67M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AYTU's P/E ratio?
Aytu BioPharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.66), so it has no meaningful P/E ratio.
How much revenue does Aytu BioPharma make?
Aytu BioPharma reported revenue of $57.57M for the twelve months to Jun 30, 2026, down 13.3% from a year earlier.
Does Aytu BioPharma pay a dividend?
No. Aytu BioPharma has not paid a cash dividend over the last twelve months.
When does Aytu BioPharma report earnings next?
Aytu BioPharma is expected to report Q1 FY2027 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has AYTU stock performed over the past year?
Including dividends, AYTU returned -13.8% over the past year, against +12.4% for the S&P 500.
How many AYTU shares are sold short?
0M shares were sold short at the latest FINRA report, 3.27% of the float, or 11.7 days of average trading volume.
Who are Aytu BioPharma's competitors?
Companies most similar to Aytu BioPharma by business, industry and size include TNXP, OCUL, DERM, ZVRA, AQST.
See a number that looks wrong?